Posts Tagged ‘obesity complications’

“Who sinned, this man or his parents?” Ancient texts remind us there is nothing new about stigma and bias toward people living with illness and disability. But still, it is jarring to encounter such expressions of weight bias as the Telegraph published not long ago. William Sitwell wrote: “Fat people are costing us all billions. […]

One more chapter opened this week in the ongoing story of diseases that improve when healthcare providers effectively treat obesity. Lilly announced topline results from a study showing that tirzepatide cuts the rate of adverse heart failure outcomes in persons with obesity and heart failure by 38% when compared to placebo. The specific form of […]

On the theme of “Is there anything GLP-1s can’t do?” a new randomized controlled trial is coming at us from the Alzheimer’s Association International Conference. It showed promising signs that a GLP-1, liraglutide, might slow the progression of Alzheimer’s disease. Liraglutide is used under the brand name Victoza to treat type 2 diabetes. At higher […]

Liver disease is frighteningly common worldwide. Metabolic dysfunction-associated steatotic liver disease, or MASLD, is an umbrella term describing conditions related to a buildup of fat in the liver. Formerly known as nonalcoholic fatty liver disease, this condition affects 1 in 4 people worldwide. Among those with type 2 diabetes, insulin resistance, obesity, or all three, […]

What should we take away from yet another suggestion that semaglutide might cut the risk of dementia? An Unexpected Finding This latest hint was a surprise. It comes from research that aimed to measure the risk of neurological and psychiatric problems associated with taking semaglutide for type 2 diabetes. Riccardo De Giorgi and colleagues were […]

Cancer might not be top of mind when most people think about the complications of obesity. But at least 13 different cancers have a clear association with obesity. A new study published Friday in JAMA Network Open examines the risk of these cancers in patients with type 2 diabetes and obesity. The primary objective was […]

At the EASL Congress 2024 in Milan, we witnessed quite a splash of new data on both survodutide and tirzepatide for MASH. Friday and Saturday gave us two headline presentations at the meeting and two publications in the New England Journal of Medicine. Lilly pronounced itself “very pleased” with the results of their SYNERGY-NASH study […]

On the opening day of the EASL Congress in Milan, we got a peek at more details on the results of the phase 2 study of tirzepatide in MASH (metabolic dysfunction associated steatohepatitis). The study, called SYNERGY-NASH, will be the subject of a late-breaking presentation on Saturday at the meeting. But the release of the […]

Yesterday, Eli Lilly and Company announced topline results for two studies of tirzepatide in people with obesity and sleep apnea. Both in people who were using CPAP devices and in those who were not, the year-long studies yielded results that independent sleep medicine researchers described as “awesome” and “phenomenal.” Clinical scientists will present the details […]

Obesity research never rests, it seems. Over the weekend, at the American College of Cardiology annual meeting and in the New England Journal of Medicine, we got a third confirmation of the benefit that semaglutide delivers to patients with obesity and heart failure. Specifically, this is about heart failure with preserved ejection fraction – HFpEF. […]